Keen Vision Acquisition Corporation Ordinary Shares (KVAC)
Automate Your Wheel Strategy on KVAC
With Tiblio's Option Bot, you can configure your own wheel strategy including KVAC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KVAC
- Rev/Share 0.0
- Book/Share 10.4209
- PB -14.5606
- Debt/Equity 0.0
- CurrentRatio 0.0426
- ROIC -0.0041
- MktCap 122274215.0
- FreeCF/Share -0.2026
- PFCF -94.2515
- PE 15.3619
- Debt/Assets 0.0
- DivYield 0
- ROE 0.088
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that data from its First-In-Human Phase 1/2a MUSIC-HFpEF clinical trial investigating its adeno-associated virus-based gene therapy candidate SRD-002 in heart failure with preserved ejection fraction (HFpEF) will be presented at the upcoming Heart Failure 2025 Congress taking place May 17-20, 2025, in Belgrade, Serbia.
Read More
Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmet need by developing a range of next-generation therapeutics, today announced that the independent Data and Safety Monitoring Board (DSMB) has completed its planned review of the MUSIC-HFrEF Phase 1b/2 clinical trial data, recommending the completion of the Phase 1b portion and clearance to initiate the Phase 2 portion of the trial evaluating the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HFrEF).
Read More
Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction
Published: March 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics, today announced that patient dosing has been completed in its MUSIC-HFrEF Phase 1/2a clinical trial of the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HErEF).
Read More
About Keen Vision Acquisition Corporation Ordinary Shares (KVAC)
- IPO Date 2023-09-15
- Website https://www.kv-ac.com
- Industry Shell Companies
- CEO Mr. Ka Chun Wong
- Employees 2